Biopharma Industry Leaders Ian Read and Clive Meanwell Join Saama Board of Directors

The Saama Board of Directors recently gained some highly respected leaders in Ian Read, former CEO and executive chairman of Pfizer, and Clive Meanwell, former CEO and founder of The Medicines Company. This news was revealed after a $430 million strategic investment in Saama by Carlyle and co-investors including McKesson Ventures, Amgen Ventures, Population Health Partners, Merck Global Health Innovation Fund, Northpond Ventures, Intermountain Ventures, and Pfizer Ventures.

“It’s an honor to join Saama’s Board of Directors and the industry experts who comprise it,” Read said of his new position.

Meanwell said, “It’s exciting to join Saama’s team in their mission of empowering pharmaceutical and biotechnology companies to bring better medical treatments to market faster, more efficiently, and with ever-greater validity.”

Now that Saama has closed its strategic investment, the company plans to expand use of AI-driven analytics to help pharmaceutical and biotech companies improve drug development and regulation submission.

Both new members have strong experience in the healthcare and biopharma industry. Read has been part of Pfizer since 1978, serving various roles such as senior vice president before becoming CEO. He maintained positions in many of Pfizer’s most impactful and fastest-growing companies. Meanwell founded The Medicines Company in 1996, serving as a board member as well as in a range of other leadership roles. He is currently executive chairman of Population Health Partners LLC.

Read the full article here.